Cue Biopharma (NASDAQ:CUE) had its target price raised by Oppenheimer from $27.00 to $32.00 in a research note issued to investors on Wednesday morning, AnalystRatings.com reports. They currently have an outperform rating on the stock.
A number of other brokerages have also recently issued reports on CUE. Stifel Nicolaus upped their price target on shares of Cue Biopharma from $21.00 to $25.00 and gave the stock a buy rating in a research note on Tuesday, April 21st. BTIG Research assumed coverage on Cue Biopharma in a research report on Tuesday, January 28th. They issued a buy rating for the company. ValuEngine raised Cue Biopharma from a sell rating to a hold rating in a research report on Tuesday, March 3rd. BidaskClub raised Cue Biopharma from a buy rating to a strong-buy rating in a research report on Saturday, April 25th. Finally, JMP Securities boosted their target price on Cue Biopharma from $22.00 to $30.00 and gave the stock an outperform rating in a research report on Friday, March 6th. Two investment analysts have rated the stock with a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the company. Cue Biopharma has a consensus rating of Buy and an average target price of $28.00.
Cue Biopharma stock traded down $0.44 during mid-day trading on Wednesday, reaching $30.10. The stock had a trading volume of 174,265 shares, compared to its average volume of 346,266. The company has a market capitalization of $868.11 million, a price-to-earnings ratio of -18.85 and a beta of 2.25. The company has a 50-day moving average price of $22.11 and a two-hundred day moving average price of $16.41. Cue Biopharma has a one year low of $6.54 and a one year high of $30.99.
Cue Biopharma (NASDAQ:CUE) last announced its quarterly earnings results on Tuesday, May 19th. The company reported ($0.48) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.33) by ($0.15). Cue Biopharma had a negative return on equity of 103.99% and a negative net margin of 959.08%. On average, analysts forecast that Cue Biopharma will post -1.33 EPS for the current year.
Several hedge funds and other institutional investors have recently added to or reduced their stakes in CUE. California Public Employees Retirement System purchased a new stake in shares of Cue Biopharma during the 4th quarter valued at about $222,000. Russell Investments Group Ltd. increased its position in shares of Cue Biopharma by 557.7% during the 4th quarter. Russell Investments Group Ltd. now owns 52,233 shares of the company’s stock valued at $828,000 after purchasing an additional 44,291 shares during the last quarter. Sigma Planning Corp increased its position in shares of Cue Biopharma by 8.6% during the 4th quarter. Sigma Planning Corp now owns 65,360 shares of the company’s stock valued at $1,038,000 after purchasing an additional 5,150 shares during the last quarter. New York State Common Retirement Fund increased its position in shares of Cue Biopharma by 74.1% during the 4th quarter. New York State Common Retirement Fund now owns 18,800 shares of the company’s stock valued at $298,000 after purchasing an additional 8,000 shares during the last quarter. Finally, State Street Corp increased its position in shares of Cue Biopharma by 16.7% during the 4th quarter. State Street Corp now owns 333,701 shares of the company’s stock valued at $5,298,000 after purchasing an additional 47,772 shares during the last quarter. 37.21% of the stock is owned by hedge funds and other institutional investors.
Cue Biopharma Company Profile
Cue Biopharma, Inc, a biopharmaceutical company, develops biologic drugs for the selective modulation of the human immune system to treat a range of cancers, chronic infectious diseases, and autoimmune disorders. Its lead drug candidate CUE-101, a protein biologic designed to target and activate antigen-specific T cells for human papilloma virus driven cancers.
Read More: Can systematic risk be avoided?
Receive News & Ratings for Cue Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cue Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.